for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

OraSure Technologies, Inc.

OSUR.OQ

Latest Trade

7.49USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.36

 - 

15.77

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.49
Open
--
Volume
--
3M AVG Volume
12.79
Today's High
--
Today's Low
--
52 Week High
15.77
52 Week Low
6.36
Shares Out (MIL)
61.72
Market Cap (MIL)
462.94
Forward P/E
30.79
Dividend (Yield %)
--

Next Event

Q3 2019 OraSure Technologies Inc Earnings Release

Latest Developments

More

OraSure Technologies Posts Q2 Earnings Per Share Of $0.07

OraSure Reports Q1 Loss Per Share $0.05

Orasure Technologies Q4 Earnings Per Share $0.16

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About OraSure Technologies, Inc.

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing.

Industry

Biotechnology & Drugs

Contact Info

150 WEBSTER ST

+1.503.6416115

http://www.orasure.com

Executive Leadership

Michael Celano

Independent Chairman of the Board

Stephen S. Tang

President, Chief Executive Officer, Director

Brian L. Smith

Vice Chairman of the Board, Executive Vice President - Innovation

Roberto E. Cuca

Chief Financial Officer

Kathleen Gallagher Weber

Executive Vice President, Business Unit Leader, Molecular Solutions at DNAG

Key Stats

3.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.2K

2018

0.2K

2019(E)

0.2K
EPS (USD)

2016

0.350

2017

0.510

2018

0.350

2019(E)

0.243
Price To Earnings (TTM)
264.46
Price To Sales (TTM)
2.80
Price To Book (MRQ)
1.61
Price To Cash Flow (TTM)
56.98
Total Debt To Equity (MRQ)
0.48
LT Debt To Equity (MRQ)
0.32
Return on Investment (TTM)
0.64
Return on Equity (TTM)
0.58

Latest News

BRIEF-OraSure Technologies Appoints New Chief Financial Officer

* CUCA WILL SUCCEED RONALD SPAIR Source text for Eikon: Further company coverage:

BRIEF-OraSure Reports Q1 Loss Per Share $0.03

* Q1 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S

BRIEF-Orasure Technologies Says Board Approved Appointment Of Michael Celano As Chairman

* ORASURE TECHNOLOGIES SAYS ON FEB 20, BOARD APPROVED APPOINTMENT OF MICHAEL CELANO AS CHAIRMAN, EFFECTIVE APRIL 1, 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2CcOGwb) Further company coverage:

BRIEF-Orasure Q4 Revenue Rose 47 Percent To $52 Million

* ORASURE ANNOUNCES RECORD 2017 FOURTH QUARTER AND FULL-YEAR FINANCIAL RESULTS

BRIEF-Orasure Technologies Announces Management Succession Plan

* ORASURE TECHNOLOGIES INC - BOARD OF DIRECTORS HAS APPOINTED STEPHEN S. TANG, AS CO'S NEW PRESIDENT AND CHIEF EXECUTIVE OFFICER, EFFECTIVE AS OF APRIL 1

BRIEF-Orasure Technologies' unit enters into $143 million deal for supply of Oragene Dx devices

* Says unit has entered into a $143 million deal for the supply of Oragene Dx devices to a consumer genomics customer - SEC filing Source text for Eikon: Further company coverage:

BRIEF-OraSure Technologies reports Q3 earnings per share $0.09

* OraSure Technologies Inc announces 2017 third quarter financial results

BRIEF-Orasure Q2 earnings per share $0.09

* Q2 earnings per share view $0.07 -- Thomson Reuters I/B/E/S

BRIEF-Orasure's OraQuick HIV Self-Test selected for next phase of STAR Project in Africa

* OraSure Technologies Inc - OraQuick HIV self-test (hivst) has been selected by UnitAid and Population Services International

BRIEF-Orasure Technologies reports agreement with Bill & Melinda Gates Foundation

* Orasure Technologies - announced agreement with Bill & Melinda Gates Foundation,will enable co to offer or a quick HIV self-test at an affordable price

BRIEF-OraSure Tech appoints Mara Aspinall to board of directors

* OraSure Technologies appoints Mara G. Aspinall to board of directors

BRIEF-Orasure announces Q1 revenue $32.5 million

* Q1 earnings per share view $0.18 -- Thomson Reuters I/B/E/S

BRIEF-Grifols says restated its 2005 agreement with Orasure Technologies

* Grifols - announces that it has restated its 2005 agreement with Orasure Technologies

BRIEF-OraSure receives global fund classification to enable HIV self-test procurement

* OraSure Technologies Inc - OraSure receives global fund classification to enable HIV self-test procurement

BRIEF-OraSure announces 2016 fourth quarter and full-year financial results

* OraSure announces 2016 fourth quarter and full-year financial results

BRIEF-Orasure Technologies announces settlement of litigation with ancestry.comdna

* Says under a settlement and license agreement executed by parties, ancestry has agreed to pay DNA Genotek a settlement fee of $12.5 million

BRIEF-Orasure Technologies appoints Stephen Tang as chairman of the board of directors

* Orasure Technologies Inc- appointment of Stephen S. Tang, as chairman of company's board of directors effective November 14, 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up